Dear Colleagues,

 

A Member of Parliament has requested the preparation of a research study on the policies implemented in European Union Member States concerning benefits, allowances, and coverage of healthcare and pharmaceutical costs for persons with Type 1 Diabetes (T1D) and Type 2 Diabetes (T2D).

In particular, we would appreciate receiving information on the current arrangements in your country regarding the following categories of benefits and services:

  1. Pharmaceutical treatment
    (coverage of insulin costs, antidiabetic medications for T2D patients, patient co-payment rates).
  2. Blood glucose monitoring systems
    (supply/reimbursement of blood glucose meters, coverage of test strips, number of test strips patients are entitled to per month or per year, and whether benefits differ between T1D and T2D patients).
  3. Continuous glucose monitoring (CGM) systems
    (coverage of sensors and consumables, duration and frequency of replacement, age-related or medical eligibility criteria for access).
  4. Insulin pumps and advanced diabetes technologies
    (coverage of insulin pumps and related consumables, and the conditions required for approval and reimbursement).
  5. Other medical supplies and equipment
    (needles and syringes, insulin delivery pens, consumables and ancillary equipment, devices for the management of hypoglycaemia, and any other items covered by the state or social insurance system).
  6. Financial and social benefits/support measures
    (monthly or annual financial allowances related to diabetes, disability or chronic illness benefits, tax relief, benefits for children and families, and special support for individuals with complications or increased care needs).
  7. Access to healthcare services
    (consultations with endocrinologists/diabetologists, laboratory testing and monitoring, diabetes education, dietetic and nursing support, and coverage of preventive screening for diabetes-related complications).

Please find attached a draft response concerning the provisions applicable in the Republic of Cyprus.

We would appreciate receiving your response by 7 December 2026, if feasible.

 

Yours sincerely,

 

Antigoni Hasikou

Senior Research, Studies and Publication Officer

House of Representatives

Republic Of Cyprus